Identifying lung disease risks in rheumatoid arthritis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to define the phenotype of Interstitial Lung Disease (ILD) in patients with rheumatoid arthritis (RA) and identify factors that predict radiologic progression in those with subclinical RA-ILD. The researchers hypothesize that there are common clinical features, genetic variants, and biologic markers that link subclinical RA-ILD with other forms of ILD, such as idiopathic pulmonary fibrosis. By understanding these connections, the study seeks to improve early detection and management of lung disease in RA patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. ≥ 45years old
2. Diagnosis of RA using the 2010 American College of Rheumatology (ACR) criteria

Exclusion Criteria:

1. Inability to give informed consent
2. Pregnant women
3. History of interstitial lung disease
4. Evidence of other causes of diffuse parenchymal lung disease such as infection, drug toxicity, other autoimmune processes, etc.
5. Subjects over the age of 90 years old or less than 45 years old

Where it's running

• University of Colorado - Anschutz Medical Campus
  Aurora, Colorado, United States Recruiting

Study contacts

• Principal investigator: Joyce S Lee, MD — University of Colorado, Denver
• Study coordinator: Haylie A Lengel
• Email: haylie.lengel@cuanschutz.edu
• Phone: 970-376-8303

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Inspiratory muscle training added to pulmonary rehabilitation for people with RA-related interstitial lung disease

  This project will test whether adding inspiratory muscle training to standard pulmonary rehabilitation helps people with rheumatoid arthritis-associated interstitial lung disease breathe easier, walk farther, gain muscle strength, feel better psychologically, and change levels of certain long noncoding RNAs.

  Recruiting Saglik Bilimleri Universitesi · Istanbul, Turkey · NCT07320846

• Identifying high-risk patients with lung disease related to rheumatoid arthritis

  This study is trying to find out which patients with lung disease related to rheumatoid arthritis are at the highest risk of their condition getting worse.

  Recruiting at 4 sites University of Colorado, Denver · San Francisco, California and 3 other locations · NCT06397677

• Using lung ultrasound to detect lung disease in rheumatoid arthritis patients

  This study is testing if lung ultrasound can help find lung disease in people with rheumatoid arthritis who have certain risk factors, comparing it to the usual chest CT scans.

  Recruiting University Hospital, Tours · Tours · NCT06235645

• Screening patients with rheumatoid arthritis for lung disease

  This study is trying to see if people with rheumatoid arthritis in Hungary have lung problems by using tests and questionnaires to check their lung health.

  Recruiting at 3 sites Polyclinic of the Hospitaller Brothers of St. John of God, Budapest · Budapest and 2 other locations · NCT05391100

• GenAI-assisted RA bone erosion risk and DMARD choice

  This study tests whether GenAI-based decision support can help doctors assess rheumatoid arthritis bone erosion risk and pick DMARDs for newly diagnosed inpatients.

  Recruiting Guang'anmen Hospital of China Academy of Chinese Medical Sciences · Beijing, Beijing Municipality · NCT07914907

• Telitacicept for primary Sjögren’s with interstitial lung disease

  This study tests whether Telitacicept helps people with primary Sjögren’s syndrome and interstitial lung disease compared with standard immunosuppressants.

  Recruiting Peking University People's Hospital · Beijing · NCT07843381

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.